| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 31 | 2021 | 1853 | 2.310 |
Why?
|
| Neoplasms | 35 | 2024 | 3035 | 2.000 |
Why?
|
| Leukemia | 10 | 2019 | 377 | 1.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1358 | 0.830 |
Why?
|
| Pyrimidines | 6 | 2024 | 420 | 0.800 |
Why?
|
| Thalidomide | 3 | 2011 | 40 | 0.760 |
Why?
|
| Arabinonucleosides | 3 | 2006 | 33 | 0.740 |
Why?
|
| Neuroblastoma | 7 | 2021 | 551 | 0.720 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2021 | 612 | 0.680 |
Why?
|
| Azepines | 3 | 2019 | 65 | 0.660 |
Why?
|
| Medical Oncology | 4 | 2010 | 247 | 0.640 |
Why?
|
| Vincristine | 2 | 2021 | 196 | 0.620 |
Why?
|
| Meningeal Neoplasms | 7 | 2011 | 217 | 0.590 |
Why?
|
| Naloxone | 1 | 2018 | 50 | 0.590 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2024 | 1318 | 0.580 |
Why?
|
| Narcotic Antagonists | 1 | 2018 | 112 | 0.560 |
Why?
|
| Maximum Tolerated Dose | 14 | 2024 | 175 | 0.540 |
Why?
|
| Salvage Therapy | 5 | 2019 | 202 | 0.520 |
Why?
|
| Child | 50 | 2024 | 25882 | 0.520 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2010 | 104 | 0.520 |
Why?
|
| Pain Management | 1 | 2018 | 202 | 0.510 |
Why?
|
| Drug Therapy | 1 | 2016 | 93 | 0.500 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2015 | 111 | 0.500 |
Why?
|
| Child, Preschool | 38 | 2024 | 14878 | 0.500 |
Why?
|
| Piperazines | 4 | 2024 | 256 | 0.490 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 91 | 0.490 |
Why?
|
| Drugs, Essential | 3 | 2023 | 7 | 0.480 |
Why?
|
| Benzimidazoles | 2 | 2022 | 136 | 0.470 |
Why?
|
| Ambulatory Care | 1 | 2018 | 415 | 0.470 |
Why?
|
| Macaca mulatta | 12 | 2011 | 513 | 0.470 |
Why?
|
| Dacarbazine | 3 | 2011 | 99 | 0.460 |
Why?
|
| Oxygenases | 1 | 2014 | 4 | 0.450 |
Why?
|
| Daunorubicin | 1 | 2014 | 27 | 0.450 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2014 | 27 | 0.450 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 3 | 2009 | 21 | 0.450 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2024 | 216 | 0.440 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2012 | 91 | 0.440 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 138 | 0.440 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 259 | 0.430 |
Why?
|
| Adolescent | 39 | 2024 | 20610 | 0.430 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2020 | 820 | 0.430 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 319 | 0.410 |
Why?
|
| Area Under Curve | 12 | 2021 | 335 | 0.410 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2014 | 135 | 0.410 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2010 | 68 | 0.410 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2024 | 830 | 0.400 |
Why?
|
| Guanine | 3 | 2011 | 63 | 0.380 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 65 | 0.380 |
Why?
|
| Camptothecin | 3 | 2008 | 79 | 0.380 |
Why?
|
| Young Adult | 21 | 2024 | 9926 | 0.370 |
Why?
|
| Informed Consent | 3 | 2009 | 345 | 0.370 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 36 | 0.370 |
Why?
|
| Enzyme Inhibitors | 5 | 2009 | 606 | 0.370 |
Why?
|
| Doxorubicin | 2 | 2014 | 301 | 0.370 |
Why?
|
| Sarcoma, Ewing | 3 | 2022 | 116 | 0.360 |
Why?
|
| Male | 50 | 2024 | 65939 | 0.350 |
Why?
|
| Humans | 69 | 2024 | 133811 | 0.350 |
Why?
|
| Patient Participation | 3 | 2010 | 239 | 0.340 |
Why?
|
| Body Composition | 2 | 2014 | 564 | 0.330 |
Why?
|
| Metabolic Clearance Rate | 5 | 2014 | 143 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2018 | 1728 | 0.330 |
Why?
|
| Obesity | 2 | 2014 | 2445 | 0.320 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2010 | 128 | 0.320 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2020 | 198 | 0.300 |
Why?
|
| Carboxylic Acids | 1 | 2008 | 25 | 0.300 |
Why?
|
| Chromatography, High Pressure Liquid | 8 | 2011 | 360 | 0.300 |
Why?
|
| Boronic Acids | 2 | 2005 | 48 | 0.300 |
Why?
|
| Rhabdomyosarcoma | 2 | 2022 | 211 | 0.300 |
Why?
|
| Infant | 21 | 2024 | 13246 | 0.290 |
Why?
|
| Cyclophosphamide | 2 | 2008 | 426 | 0.290 |
Why?
|
| Oligopeptides | 1 | 2008 | 121 | 0.290 |
Why?
|
| Pyrazines | 2 | 2005 | 73 | 0.290 |
Why?
|
| Physician-Patient Relations | 2 | 2009 | 448 | 0.290 |
Why?
|
| Female | 43 | 2024 | 71840 | 0.270 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2024 | 50 | 0.270 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2024 | 67 | 0.270 |
Why?
|
| Medulloblastoma | 2 | 2012 | 571 | 0.270 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 1160 | 0.270 |
Why?
|
| Phthalazines | 2 | 2024 | 15 | 0.260 |
Why?
|
| Infusions, Intravenous | 8 | 2005 | 569 | 0.250 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 2948 | 0.250 |
Why?
|
| Indoles | 2 | 2004 | 202 | 0.250 |
Why?
|
| Leukemia, T-Cell | 1 | 2005 | 11 | 0.240 |
Why?
|
| Topotecan | 3 | 2012 | 50 | 0.240 |
Why?
|
| Ethics, Medical | 2 | 2007 | 401 | 0.240 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 100 | 0.230 |
Why?
|
| DNA Repair | 3 | 2024 | 638 | 0.230 |
Why?
|
| Cyclopentanes | 1 | 2024 | 22 | 0.220 |
Why?
|
| Cyclin D1 | 1 | 2004 | 123 | 0.220 |
Why?
|
| Cyclins | 1 | 2004 | 105 | 0.220 |
Why?
|
| Depsipeptides | 1 | 2004 | 11 | 0.220 |
Why?
|
| Carbazoles | 1 | 2004 | 34 | 0.220 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 57 | 0.210 |
Why?
|
| Cell Line, Tumor | 6 | 2018 | 3799 | 0.210 |
Why?
|
| Cisplatin | 2 | 2004 | 288 | 0.210 |
Why?
|
| Parents | 3 | 2009 | 1072 | 0.210 |
Why?
|
| Rhabdoid Tumor | 1 | 2023 | 56 | 0.210 |
Why?
|
| Pyridines | 1 | 2024 | 250 | 0.200 |
Why?
|
| Methotrexate | 2 | 2020 | 355 | 0.200 |
Why?
|
| Glioma | 2 | 2022 | 535 | 0.200 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2024 | 222 | 0.190 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2024 | 455 | 0.180 |
Why?
|
| Models, Theoretical | 1 | 2004 | 397 | 0.180 |
Why?
|
| Adult | 19 | 2024 | 31823 | 0.180 |
Why?
|
| Dactinomycin | 1 | 2021 | 66 | 0.180 |
Why?
|
| Treatment Outcome | 14 | 2020 | 13114 | 0.180 |
Why?
|
| Maytansine | 1 | 2020 | 4 | 0.170 |
Why?
|
| Neurofibrosarcoma | 1 | 2020 | 5 | 0.170 |
Why?
|
| Injections, Spinal | 6 | 2011 | 136 | 0.170 |
Why?
|
| Pulmonary Blastoma | 1 | 2020 | 11 | 0.170 |
Why?
|
| Sarcoma, Synovial | 1 | 2020 | 22 | 0.170 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 57 | 0.160 |
Why?
|
| Drug Synergism | 3 | 2009 | 239 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2019 | 234 | 0.160 |
Why?
|
| Drug Interactions | 3 | 2012 | 260 | 0.160 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2024 | 34 | 0.160 |
Why?
|
| Wilms Tumor | 1 | 2020 | 119 | 0.150 |
Why?
|
| Cerebrospinal Fluid | 3 | 2004 | 99 | 0.150 |
Why?
|
| Research Subjects | 1 | 2019 | 55 | 0.150 |
Why?
|
| Drug Administration Schedule | 6 | 2018 | 748 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 128 | 0.150 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 2011 | 18 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 168 | 0.150 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2014 | 89 | 0.140 |
Why?
|
| Furans | 1 | 2018 | 30 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 1049 | 0.140 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 447 | 0.140 |
Why?
|
| Ketones | 1 | 2018 | 29 | 0.140 |
Why?
|
| Research Personnel | 1 | 2019 | 135 | 0.140 |
Why?
|
| Aurora Kinase A | 1 | 2018 | 38 | 0.140 |
Why?
|
| Recurrence | 3 | 2019 | 1470 | 0.140 |
Why?
|
| Cell Cycle Proteins | 2 | 2019 | 709 | 0.140 |
Why?
|
| Health Services Accessibility | 2 | 2023 | 658 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2020 | 298 | 0.140 |
Why?
|
| Animals | 16 | 2019 | 36222 | 0.130 |
Why?
|
| Cell Survival | 2 | 2012 | 886 | 0.130 |
Why?
|
| Health Policy | 1 | 2019 | 233 | 0.130 |
Why?
|
| Chronic Pain | 1 | 2018 | 149 | 0.130 |
Why?
|
| Mass Spectrometry | 3 | 2006 | 367 | 0.120 |
Why?
|
| Health Care Rationing | 1 | 2016 | 63 | 0.120 |
Why?
|
| Brain Neoplasms | 2 | 2004 | 1406 | 0.120 |
Why?
|
| Palliative Care | 1 | 2019 | 466 | 0.110 |
Why?
|
| Deoxycytidine | 2 | 2007 | 84 | 0.110 |
Why?
|
| Pediatrics | 3 | 2010 | 1221 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2022 | 407 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 111 | 0.110 |
Why?
|
| Prodrugs | 2 | 2006 | 64 | 0.110 |
Why?
|
| Separase | 1 | 2014 | 29 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2018 | 372 | 0.110 |
Why?
|
| Absorptiometry, Photon | 1 | 2014 | 206 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 469 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 66 | 0.100 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 300 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2019 | 555 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 2 | 2005 | 1106 | 0.100 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 203 | 0.100 |
Why?
|
| Injections, Intravenous | 3 | 2008 | 251 | 0.100 |
Why?
|
| Mutation | 2 | 2024 | 6350 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1340 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2008 | 1383 | 0.100 |
Why?
|
| Meningitis, Aseptic | 1 | 2012 | 14 | 0.100 |
Why?
|
| Haplotypes | 1 | 2014 | 559 | 0.100 |
Why?
|
| Aurora Kinase B | 1 | 2012 | 8 | 0.100 |
Why?
|
| Aurora Kinases | 1 | 2012 | 28 | 0.100 |
Why?
|
| Pyrroles | 2 | 2024 | 185 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2024 | 211 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2014 | 507 | 0.090 |
Why?
|
| Survival Rate | 4 | 2019 | 2216 | 0.090 |
Why?
|
| Brain Stem Neoplasms | 1 | 2011 | 47 | 0.090 |
Why?
|
| Genomics | 1 | 2019 | 1678 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 897 | 0.090 |
Why?
|
| Half-Life | 4 | 2021 | 162 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2010 | 34 | 0.090 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 157 | 0.080 |
Why?
|
| Prognosis | 4 | 2019 | 5071 | 0.080 |
Why?
|
| Altruism | 1 | 2010 | 25 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1783 | 0.080 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 4760 | 0.080 |
Why?
|
| United States | 6 | 2024 | 11760 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 203 | 0.080 |
Why?
|
| DNA Mismatch Repair | 1 | 2009 | 53 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2020 | 1593 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2010 | 180 | 0.080 |
Why?
|
| Apoptosis | 3 | 2018 | 1933 | 0.080 |
Why?
|
| Tissue Distribution | 2 | 2019 | 400 | 0.080 |
Why?
|
| Acyclovir | 1 | 2008 | 47 | 0.070 |
Why?
|
| Bortezomib | 2 | 2005 | 71 | 0.070 |
Why?
|
| Valine | 1 | 2008 | 116 | 0.070 |
Why?
|
| Carmustine | 1 | 2008 | 25 | 0.070 |
Why?
|
| Confidentiality | 1 | 2008 | 106 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2014 | 1722 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 5455 | 0.070 |
Why?
|
| Human Experimentation | 1 | 2007 | 36 | 0.070 |
Why?
|
| Ethics, Research | 1 | 2007 | 55 | 0.070 |
Why?
|
| Carboplatin | 2 | 2004 | 87 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2007 | 110 | 0.070 |
Why?
|
| Administration, Intravenous | 2 | 2020 | 162 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1880 | 0.060 |
Why?
|
| DNA Damage | 2 | 2024 | 547 | 0.060 |
Why?
|
| Valproic Acid | 1 | 2007 | 168 | 0.060 |
Why?
|
| Benzamides | 2 | 2023 | 126 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 305 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 92 | 0.060 |
Why?
|
| Adenine Nucleotides | 1 | 2005 | 39 | 0.060 |
Why?
|
| Risk | 1 | 2007 | 830 | 0.060 |
Why?
|
| Administration, Oral | 3 | 2018 | 719 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 1013 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 182 | 0.060 |
Why?
|
| Imidazoles | 1 | 2006 | 219 | 0.060 |
Why?
|
| Cyclin D3 | 1 | 2004 | 11 | 0.060 |
Why?
|
| Cyclin D2 | 1 | 2004 | 15 | 0.060 |
Why?
|
| Cyclin D | 1 | 2024 | 8 | 0.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2004 | 66 | 0.060 |
Why?
|
| NEDD8 Protein | 1 | 2024 | 12 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 204 | 0.060 |
Why?
|
| Thiophenes | 1 | 2005 | 72 | 0.060 |
Why?
|
| Retinoblastoma Protein | 1 | 2004 | 86 | 0.060 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 43 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2004 | 90 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 52 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 6602 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 82 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2024 | 104 | 0.050 |
Why?
|
| Quinazolines | 1 | 2005 | 185 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2024 | 60 | 0.050 |
Why?
|
| SMARCB1 Protein | 1 | 2023 | 48 | 0.050 |
Why?
|
| Anemia | 1 | 2007 | 350 | 0.050 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2023 | 69 | 0.050 |
Why?
|
| Phenylacetates | 1 | 2003 | 22 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 718 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 34 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2023 | 1350 | 0.050 |
Why?
|
| Middle Aged | 4 | 2018 | 29287 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 61 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2024 | 351 | 0.050 |
Why?
|
| Teratoma | 1 | 2023 | 131 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 323 | 0.050 |
Why?
|
| Physicians | 1 | 2009 | 640 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 253 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2004 | 624 | 0.050 |
Why?
|
| Glutamine | 1 | 2003 | 217 | 0.050 |
Why?
|
| Mixed Function Oxygenases | 1 | 2002 | 36 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 370 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 93 | 0.050 |
Why?
|
| Europe | 1 | 2023 | 380 | 0.050 |
Why?
|
| Phenytoin | 1 | 2002 | 63 | 0.050 |
Why?
|
| Lymphoma | 1 | 2005 | 331 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2024 | 2177 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 444 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 142 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 178 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2022 | 245 | 0.040 |
Why?
|
| CD56 Antigen | 1 | 2020 | 29 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 625 | 0.040 |
Why?
|
| Decision Making | 1 | 2006 | 702 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 9 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 4006 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1717 | 0.040 |
Why?
|
| DNA Repair Enzymes | 2 | 2011 | 48 | 0.040 |
Why?
|
| DNA Modification Methylases | 2 | 2011 | 52 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 59 | 0.040 |
Why?
|
| Drugs, Generic | 1 | 2019 | 14 | 0.040 |
Why?
|
| Community Participation | 1 | 2019 | 42 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 92 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 303 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2002 | 396 | 0.040 |
Why?
|
| Patient Rights | 1 | 2019 | 51 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2005 | 3746 | 0.040 |
Why?
|
| Focus Groups | 1 | 2019 | 213 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 1312 | 0.040 |
Why?
|
| Family | 2 | 2016 | 596 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 113 | 0.040 |
Why?
|
| Microtubules | 1 | 2018 | 132 | 0.030 |
Why?
|
| Algorithms | 1 | 2005 | 1736 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2019 | 334 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 345 | 0.030 |
Why?
|
| Time Factors | 2 | 2004 | 6554 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 307 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2011 | 510 | 0.030 |
Why?
|
| Dexamethasone | 2 | 2012 | 281 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 817 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 158 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 135 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 436 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2011 | 1488 | 0.030 |
Why?
|
| Rhodamines | 1 | 2014 | 22 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1733 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1491 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2017 | 8632 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2014 | 161 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2023 | 2730 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2014 | 110 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 399 | 0.030 |
Why?
|
| Infusions, Intraventricular | 1 | 2012 | 14 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 334 | 0.020 |
Why?
|
| Antibodies | 1 | 2014 | 372 | 0.020 |
Why?
|
| Mice | 3 | 2019 | 18936 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2020 | 17577 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 118 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2014 | 457 | 0.020 |
Why?
|
| Age Factors | 2 | 2008 | 2987 | 0.020 |
Why?
|
| Peptides | 1 | 2014 | 863 | 0.020 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2008 | 21 | 0.020 |
Why?
|
| State Government | 1 | 2008 | 30 | 0.020 |
Why?
|
| Government Regulation | 1 | 2008 | 43 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1145 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 3422 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 1165 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2007 | 14 | 0.020 |
Why?
|
| Pharmacokinetics | 1 | 2007 | 16 | 0.020 |
Why?
|
| Microsatellite Instability | 1 | 2007 | 40 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 2008 | 41 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2008 | 233 | 0.020 |
Why?
|
| Hematinics | 1 | 2007 | 60 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 319 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2006 | 63 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 251 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2559 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2007 | 322 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 288 | 0.010 |
Why?
|
| Pulse Therapy, Drug | 1 | 2004 | 9 | 0.010 |
Why?
|
| Biological Availability | 1 | 2004 | 151 | 0.010 |
Why?
|
| Meningitis | 1 | 2005 | 101 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2004 | 49 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 332 | 0.010 |
Why?
|
| Biotransformation | 1 | 2003 | 56 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2003 | 49 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2004 | 211 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 158 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 2002 | 64 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 772 | 0.010 |
Why?
|
| Ondansetron | 1 | 2002 | 10 | 0.010 |
Why?
|
| Melphalan | 1 | 2002 | 46 | 0.010 |
Why?
|
| Phenobarbital | 1 | 2002 | 35 | 0.010 |
Why?
|
| Pineal Gland | 1 | 2002 | 22 | 0.010 |
Why?
|
| Pinealoma | 1 | 2002 | 23 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 103 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 826 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 793 | 0.010 |
Why?
|
| Etoposide | 1 | 2002 | 120 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2002 | 60 | 0.010 |
Why?
|
| Cranial Irradiation | 1 | 2002 | 72 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 1485 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 2771 | 0.010 |
Why?
|
| Pregnancy | 1 | 2014 | 7599 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1853 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2008 | 5219 | 0.010 |
Why?
|
| Models, Biological | 1 | 2003 | 1532 | 0.010 |
Why?
|
| Seizures | 1 | 2002 | 889 | 0.010 |
Why?
|
| Disease Progression | 1 | 2002 | 2255 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2002 | 1191 | 0.010 |
Why?
|